Drug
Entrectinib clinical trials
Also written Rozlytrek, RXDX-101 and RO7102122.
- studies test it
- 29
- open now
- 9
- in phase 3
- 6
- first study started
- 2014
Keep track of what changes. Save the entrectinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 3 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 8
- Phase 2
- 19
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 15
Hoffmann-La Roche (11) · OHSU Knight Cancer Institute (3) · Genentech, Inc. (3) · Cancer Research UK (2) · Alliance for Clinical Trials in Oncology (1) · Jules Bordet Institute (1) · Fondazione per la Medicina Personalizzata (1) · Peking University Shenzhen Hospital (1)
Often tested with
Tested in the same studies.
Alectinib (12) · Atezolizumab (11) · Vemurafenib (9) · Cobimetinib (8) · Ipatasertib (5) · Ado-Trastuzumab Emtansine (5) · Pralsetinib (5) · Pertuzumab (5)
Studies
Open first, then newest update. How each study uses entrectinib is read from its arms, and is right about nine times in ten.
Testing it · 29
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 2Genentech, Inc.NCT04302025Written as Entrectinib
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Written as Entrectinib
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886Written as Entrectinib
- Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS TumorsRecruitingPhase 2St. Jude Children's Research HospitalNCT06528691Written as Entrectinib
- DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT05770544Written as Entrectinib
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086Written as Entrectinib
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as Entrectinib
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Entrectinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Entrectinib
- Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaActive, not recruitingPhase 1OHSU Knight Cancer InstituteNCT05396859Written as Entrectinib
- Genetic Testing in Guiding Treatment for Patients With Brain MetastasesActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT03994796Written as Entrectinib
- Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsActive, not recruitingPhase 1/2Hoffmann-La RocheNCT02650401Written as Entrectinib
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Written as Entrectinib
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3Hoffmann-La RocheNCT03178552Written as Entrectinib
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Active, not recruitingPhase 2Hoffmann-La RocheNCT02568267Written as Entrectinib
- A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive, not recruitingPhase 3Hoffmann-La RocheNCT04603807Written as Entrectinib
- A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Hoffmann-La RocheNCT05170204Written as Entrectinib
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedPhase 2Hoffmann-La RocheNCT03498521Written as Entrectinib
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedPhase 2Genentech, Inc.NCT04632992Written as Entrectinib
- Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)Active, not recruitingPhase 2Jules Bordet InstituteNCT04551495Written as Entrectinib
Codes
What other systems call entrectinib · ClinicalTrials.gg INT000452
- MeSH (NLM) C000607349entrectinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) L5ORF0AN1IENTRECTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2197862One source FDA
- Wikidata Q25323953entrectinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114984EntrectinibOne source FDA
- DrugBank DB11986One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000607349 | entrectinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | L5ORF0AN1I | ENTRECTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2197862 | — | One source FDA |
| Wikidata | Q25323953 | entrectinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114984 | Entrectinib | One source FDA |
| DrugBank | DB11986 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.